BR112022001062A2 - Inibidores de ferroportina para o uso no tratamento de beta-talassemia dependente de transfusão (tdt) - Google Patents

Inibidores de ferroportina para o uso no tratamento de beta-talassemia dependente de transfusão (tdt)

Info

Publication number
BR112022001062A2
BR112022001062A2 BR112022001062A BR112022001062A BR112022001062A2 BR 112022001062 A2 BR112022001062 A2 BR 112022001062A2 BR 112022001062 A BR112022001062 A BR 112022001062A BR 112022001062 A BR112022001062 A BR 112022001062A BR 112022001062 A2 BR112022001062 A2 BR 112022001062A2
Authority
BR
Brazil
Prior art keywords
thalassemia
transfusion
tdt
treatment
dependent beta
Prior art date
Application number
BR112022001062A
Other languages
English (en)
Inventor
Franz Dürrenberger
Naja Nyffenegger
Patrick Altermatt
Vania Manolova
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of BR112022001062A2 publication Critical patent/BR112022001062A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

inibidores de ferroportina para o uso no tratamento de beta-talassemia dependente de transfusão (tdt). a invenção se refere ao uso de compostos inibidores de ferroportina da fórmula geral (i) para tratar ß-talassemia dependente de transfusão.
BR112022001062A 2019-07-19 2020-07-17 Inibidores de ferroportina para o uso no tratamento de beta-talassemia dependente de transfusão (tdt) BR112022001062A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19187248 2019-07-19
EP20174230 2020-05-12
PCT/EP2020/070391 WO2021013771A1 (en) 2019-07-19 2020-07-17 Ferroportin-inhibitors for the use in the treatment of transfusion-dependent beta-thalassemia (tdt)

Publications (1)

Publication Number Publication Date
BR112022001062A2 true BR112022001062A2 (pt) 2022-03-15

Family

ID=71661870

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022001062A BR112022001062A2 (pt) 2019-07-19 2020-07-17 Inibidores de ferroportina para o uso no tratamento de beta-talassemia dependente de transfusão (tdt)

Country Status (11)

Country Link
US (1) US20220273634A1 (pt)
EP (1) EP3999059A1 (pt)
JP (1) JP7554253B2 (pt)
KR (1) KR20220042149A (pt)
CN (1) CN114302882A (pt)
AU (1) AU2020316632A1 (pt)
BR (1) BR112022001062A2 (pt)
CA (1) CA3147696A1 (pt)
IL (1) IL289756A (pt)
MX (1) MX2022000782A (pt)
WO (1) WO2021013771A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3232329A1 (en) 2021-09-21 2023-03-30 Wilm Buhr N-substituted ferroportin inhibitors
WO2024083980A1 (en) 2022-10-21 2024-04-25 Vifor (International) Ag Bicyclic ferroportin inhibitors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2313270C (en) * 2000-06-30 2011-09-13 Apotex Inc. Use of deferiprone in treating and preventing iron-induced cardiac disease
US8048894B2 (en) * 2007-04-18 2011-11-01 Amgen Inc. Quinolones and azaquinolones that inhibit prolyl hydroxylase
AU2010254920C1 (en) * 2009-06-04 2016-03-10 Nissan Chemical Industries, Ltd. Heterocyclic compound and hematopoietic stem cell amplifier
CA2857990A1 (en) 2011-12-09 2013-06-13 Ferrokin Biosciences, Inc. Oral formulations for treating metal overload
EP3071201A4 (en) * 2013-11-22 2017-04-26 University of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
TN2017000468A1 (en) 2015-05-13 2019-04-12 Acceleron Pharma Inc TREATMENT OF BETA-THALASSEMIA USING ACTRIl LIGAND TRAPS.
SG10202005377VA (en) 2015-10-23 2020-07-29 Vifor Int Ag Novel ferroportin inhibitors
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
ES2934492T3 (es) 2018-12-13 2023-02-22 Global Blood Therapeutics Inc Inhibidores de ferroportina y métodos de uso

Also Published As

Publication number Publication date
EP3999059A1 (en) 2022-05-25
MX2022000782A (es) 2022-04-18
WO2021013771A1 (en) 2021-01-28
CN114302882A (zh) 2022-04-08
AU2020316632A1 (en) 2022-02-24
CA3147696A1 (en) 2021-01-28
US20220273634A1 (en) 2022-09-01
JP2022541782A (ja) 2022-09-27
KR20220042149A (ko) 2022-04-04
JP7554253B2 (ja) 2024-09-19
IL289756A (en) 2022-03-01

Similar Documents

Publication Publication Date Title
CY1124046T1 (el) Ενωσεις ν-((ετ)αρυλμεθυλ)-ετεροαρυλ-καρβοξαμιδιων ως αναστολεις καλλικρεϊνης πλασματος
CL2022001731A1 (es) Inhibidores de egfr.
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
EA201691421A1 (ru) Гетероарилы и их применение
MD20160118A2 (ro) Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1
EA202193015A1 (ru) Ингибиторы cdk
EA201792259A1 (ru) Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
UA111382C2 (uk) Інгібітори протеїнкінази
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
EA201692480A1 (ru) Фармацевтическая композиция
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
BR112019020421A8 (pt) Derivados de 2-oxo- tiazóis como inibidores de a2a e compostos para uso no tratamento de cânceres
BR112022001062A2 (pt) Inibidores de ferroportina para o uso no tratamento de beta-talassemia dependente de transfusão (tdt)
EA202192575A1 (ru) Соединения dbait в сочетании с ингибиторами киназ для лечения рака
EA202090900A1 (ru) Ингибиторы иммунопротеасом
IL314033A (en) RAS inhibitors
BR112018008506B8 (pt) Compostos inibidores do fator xia, composição farmacêutica e usos dos mesmos
BR112012024422A2 (pt) uso de novos inibidores pan-cdk para tratamento de tumores
CL2022001357A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
EA201990952A1 (ru) ПИРИДОНОВОЕ СОЕДИНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРА c-Met
BR112022002222A2 (pt) Derivados de quinolina como inibidores de proteínas quinases
MA52891A (fr) Dérivés aza-indoliques utilisés comme inhibiteurs de rho-kinase
EA202191051A1 (ru) Ингибитор аврора-киназы a для применения для лечения нейробластомы